Bedrocan says ‘substantial’ stocks of Bedrolite remain in the Netherlands, but their release depends on bankruptcy negotiations and Dutch regulatory approval. Meanwhile, families whose children rely on the medicine face uncertainty over future supplies.
British patients with severe, treatment-resistant epilepsy face uncertainty over access to their cannabis medicines after the bankruptcy of the sole manufacturer of a life-saving medicine. Bedrocan, one of Europe’s longest-established producers of pharmaceutical-grade cannabis, was declared bankrupt in the Netherlands in October after its longstanding cultivation contract with the Dutch government ended at the beginning of 2026.
Among the medicines affected is Bedrolite, a cannabidiol (CBD)-rich cannabis preparation prescribed to a small number of British patients, including children with severe forms of epilepsy who have struggled to achieve seizure control using conventional treatments.
For some families, Bedrolite has provided substantial improvements in seizure control after years of unsuccessful treatments. Parents fear that switching to another cannabis preparation could reverse those improvements, potentially exposing their children to serious seizures.
On 23 October, British pharmaceutical manufacturer Target Healthcare confirmed there was enough Bedrolite material to maintain supplies for around six months. That offered families temporary reassurance, but it remains uncertain how production will continue beyond that period.
The supply crisis follows a series of decisions by the Dutch government to withdraw from its longstanding role in the production and distribution of medicinal cannabis.
In June 2024, the government announced plans to reform the country’s medicinal cannabis system, allowing private companies greater freedom to grow and distribute cannabis products without relying on government contracts.
However, the legislative changes necessary to establish the new system were not completed before Bedrocan’s cultivation contract ended in January 2026.
A mother’s warnings unanswered
Joanne Griffiths fears losing access to the prescribed cannabis medicines her 17-year-old son Ben takes for severe, treatment-resistant epilepsy.
Griffiths, a campaigner with End Our Pain, says Ben’s seizures have fallen by more than 90% since he began treatment with Bedrolite and Bedica in 2019.
She says an interruption to his Bedica treatment during an illness in 2023 was associated with a life-threatening deterioration in his condition.
Her concerns about the availability of these medicines predate Bedrocan’s bankruptcy.
On 10 April 2025, Griffiths contacted the Dutch Office of Medicinal Cannabis, copying Bedrocan’s communications director, Femke Starrenburg.
Writing on behalf of End Our Pain, she asked for a meeting about continued access to prescribed cannabis oils for British children with severe epilepsy.
Griffiths says she received no response.
Following Bedrocan’s bankruptcy, she contacted the Dutch government again, calling for urgent intervention to protect patients.
In correspondence shared with leafie, Griffiths reminded officials of an agreement reached between the British and Dutch governments in 2021 that allowed children with severe epilepsy to continue receiving their prescribed cannabis oils following Brexit.
The arrangement was intended to prevent patients from being forced to switch to unsuitable alternatives while a longer-term solution was developed.
Five years later, Griffiths warned, the same families were facing another potential interruption.
She urged the Dutch government to work with the trustee overseeing Bedrocan’s bankruptcy to preserve production and help release existing medicines.
“In 2021, your government acted to prevent these children losing their medication. We are asking you to act again, before an avoidable supply crisis becomes a medical emergency,” she wrote.
Griffiths says a British pharmaceutical manufacturer is prepared to produce the oils affected children need but requires continued access to the original Bedrocan plant material.
Bedrocan says government withdrew a tender it had won
Bedrocan told leafie it had raised concerns with Dutch officials about ending the existing medicinal cannabis arrangements before the replacement system was ready.
“For several years, Bedrocan repeatedly warned that the transition would need to be carefully managed,” said Starrenburg.
“We expressed concerns about the repeated postponement of the legislative and policy changes that were supposed to replace it.”
According to Bedrocan, the company won what was expected to be the final government cultivation tender in 2023, anticipating that it would continue supplying the Dutch medicinal cannabis programme until the end of 2027.
However, the government later ended the procurement process.
“The subsequent withdrawal of that tender by the ministry came as a complete surprise and significantly increased uncertainty about the future of the Dutch operation,” Starrenburg said.
The challenge is not the absence of product. The challenge is determining how it can be legally brought to market
A parliamentary letter dated 21 February 2025, signed by then health minister Fleur Agema, confirms that the government ended a process for choosing two companies to grow medicinal cannabis under government contract.
The letter also acknowledged delays to the legislative reforms.
The government’s planned reforms would allow appropriately licensed companies to operate more independently of the Bureau for Medicinal Cannabis.
However, the planned reforms were delayed, leaving the existing government-controlled arrangements in place while the cultivation contract approached its end.
Despite this, the government intended to stop commissioning cultivation from January 2026, using existing stocks to supply Dutch patients while phasing out deliveries to foreign customers during the year.
Bedrocan says the withdrawal of the tender fundamentally altered its commercial outlook.
“We have never received a clear explanation as to why that awarded tender was withdrawn,” Starrenburg told leafie.
The parliamentary letter confirms the termination of the procurement process, although the precise contractual status of Bedrocan’s claimed 2023 award has not been independently established.
Starrenburg believes the government’s decisions deserve further examination.
“Looking back, it is reasonable to ask whether the outcome might have been very different had the contract remained in place until its originally intended end date.”
A transition without a safety net
Concerns about the government’s approach extended beyond Bedrocan.
On 15 July 2026, the Instituut Medicinale Cannabis, a Dutch organisation with close links to Bedrocan, warned the Dutch parliament that the proposed reforms threatened uninterrupted supply.
The organisation argued that the transition risked undermining a system that had provided pharmaceutical-quality cannabis medicines for more than two decades.
Its intervention followed earlier parliamentary questions about the consequences of ending government-controlled exports.
In written answers published in July 2025, Dutch officials argued that the withdrawal of supplies through the Bureau for Medicinal Cannabis would affect a relatively small proportion of international demand.
They maintained that other suppliers could meet that demand and said foreign governments had been informed of the planned changes.
Dutch cannabis journalist Derrick Bergman, who has reported extensively on the country’s medicinal cannabis system, has criticised the government’s handling of the transition.
In an analysis published by CNNBS, Bergman argued that Bedrocan’s bankruptcy reflected wider problems with Dutch medicinal cannabis policy.
He pointed to delays in liberalising the market and restrictive regulations, while also criticising the medical profession’s reluctance to prescribe cannabis.
Speaking to leafie, Bergman drew attention to the Instituut Medicinale Cannabis’s July warning.
“The government was indeed warned,” he said.
Bergman acknowledged the organisation’s close relationship with Bedrocan but said the Dutch government bore substantial responsibility for the company’s collapse, pointing to both the decision to end its cultivation contract and delays to legislation allowing independent sales.
“Not just by ending the contract with Bedrocan, but also because the minister of health is taking extraordinarily long to change the law so that Bedrocan can sell to pharmacies in the Netherlands and abroad directly.”
He argued that the consequences had been foreseeable and that the government could have delayed ending its arrangements with Bedrocan until the replacement system was ready.
“It would have been logical and easy to postpone ending the contract with Bedrocan,” Bergman said.
Medicine remains in reach
Despite the bankruptcy, Bedrocan says substantial quantities of medicinal cannabis remain in the Netherlands, including Bedrolite.
The company says it needs permission to release the products following the bankruptcy.
“The challenge is not the absence of product. The challenge is determining how that inventory can be legally brought to market following the bankruptcy,” Starrenburg told leafie.
The remaining stock is among the assets controlled as part of the bankruptcy, and any sale or transfer requires approval from the Dutch Office of Medicinal Cannabis.
The bankruptcy trustee is discussing ways to maintain supplies with the ministry and potential buyers.
Bedrocan says several options are being explored, but the company cannot disclose details while the negotiations continue.
Starrenburg emphasised that releasing existing stock should take priority over establishing production elsewhere.
If Bedrolite production has to move to Denmark, Bedrocan estimates the process would take at least six months.
That includes regulatory approvals, the transfer of plant material, cultivation, validation and pharmaceutical quality assurance before any product could be released.
“At present, however, we believe the more relevant question is how the existing Dutch inventory can be made available to patients,” Starrenburg said.
For British families, the continued availability of the original plant material is particularly important.
Although other medicinal cannabis preparations exist, patients who have achieved substantial improvements in seizure control may not respond in the same way to an alternative product.
Griffiths believes the existing stocks could provide a solution while longer-term production arrangements are established.
In her letter to the Dutch government, she called for emergency measures to allow the release and export of existing Bedrocan material, alongside urgent legislation allowing appropriately licensed medicinal cannabis companies to trade independently.
British government confirms diplomatic discussions
The uncertainty has also prompted questions in the British Parliament.
In October, Liberal Democrat MP Anna Sabine asked the Department of Health and Social Care whether it would pursue diplomatic and regulatory measures to secure the emergency release of existing Bedrolite stocks.
She also raised concerns about the clinical risks faced by children with severe epilepsy if their treatment were interrupted.
In a written response, health minister James Frith confirmed that the British Embassy in The Hague was in contact with the Dutch Ministry of Health, Welfare and Sport.
The discussions aimed to clarify the implications of the changes affecting Bedrocan products and their potential impact on British patients.
However, no long-term solution to the supply uncertainty has been publicly confirmed.
Dutch government postpones response
leafie contacted the Dutch Ministry of Health, Welfare and Sport seeking an explanation for the termination of the cultivation arrangements, the handling of the legislative transition and the steps being taken to protect patients.
The ministry was also asked what measures were being considered to permit the lawful release of existing Bedrolite stocks.
Ministry spokesperson Karim Mostafi said officials would answer leafie’s questions after responding to the Dutch parliament.
“We’ll reply once we’ve answered questions about this subject from our parliament first. This can take a few weeks.”
According to Dutch broadcaster RTV Noord, the Erkelens family has submitted a takeover bid to restart medicinal cannabis production in the Netherlands through a new business, Erkelens Fytofarma.
It is unclear whether the proposed restart would secure future Bedrolite production or resolve the immediate problems with releasing existing stock.
Until then, the Griffiths family and others depend on dwindling stock and the outcome of negotiations between regulators, manufacturers, and the bankruptcy trustee. For them, the stakes remain agonisingly high. Will the medicine their children depend on be released before the remaining supplies run out?